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Abstract: Ochratoxin A (OTA) is a mycotoxin naturally occurring in different foods. OTA 
is arguably a risk factor for Balkan endemic nephropathy (BEN). The aims of this study 
are to (1) test the OTA-BEN association in BEN-groups and controls and (2) determine 
whether urine β2-microglobulin, a marker of impaired ability of the kidneys to re-absorb, 
is related to OTA. BEN patients had significantly higher OTA serum levels. Within the 
offspring, OTA was significantly related to higher β2-microglobulin excretion. OTA 
(2005/2006) was related to a higher incidence of BEN after 2008, providing further 
evidence that OTA is a risk factor for BEN. 
Keywords: BEN; ochratoxin A; β2-microglobulin 
 
1. Introduction  
Ochratoxin A (OTA) is a potently nephrotoxic and carcinogenic fungal metabolite, the potency varying 
between species and sexes, and it is also teratogenic and immunotoxic [1,2]. In 1993, the International 
Agency for Research on Cancer classified OTA as a possible human carcinogen (Group 2B) [1,2]. In 
various types of food stored under specific conditions, it is a naturally occurring contaminant, 
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produced by Penicillium verrucosum and Aspergillus species and known as “store” fungi [2–4]. There is 
considerable information on the occurrence of OTA in cereals [2,5,6], beer [7,8], coffee beans [2,9,10], 
cocoa beans [11,12], dried vine fruit, wine, grape juice [2,13–15], and spices [16,17]. It has been 
demonstrated that OTA is typical contaminant of food products traditionally used by Bulgarian 
populations [18–21]. 
The ubiquitous occurrence of OTA is considered as a human health risk. Concentrations in human 
samples have been measured in many populations. In most European countries, the reported mean 
concentration of OTA in serum/plasma of healthy individuals did not exceed 1.0 ng/mL. Mean OTA 
concentrations in blood samples were: 0.21 ng/mL in Poland (range 1.0–13.0 ng/mL) [22] and   
0.75 ng/mL in Germany (range 0.1–8.4 ng/mL) [23]. Comparable levels were detected in serum 
samples: 0.63 ng/mL in Czech Republic [24] and 0.56 ng/mL in Italy (range 0.12–2.84 ng/mL) [25]. 
Higher mean values of 1.5, 2.3 and 1.6 ng/mL in blood samples (1986, 1987, and 1988, respectively) 
were found in a Danish study [26]. Studies have shown that OTA is not only just a European problem, 
but an international. An investigation by Scott et al. [27], in Canada demonstrated that OTA was found 
in all plasma samples with a mean concentration of 0.88 ng/mL (range 0.29–2.37 ng/mL). A study in 
Tokyo [28] suggested that the population was frequently exposed to mycotoxin, although the levels in 
plasma were far less than that reported in Europe and Canada. In Lebanon OTA was detectible in 33% 
of human plasma samples with a mean of 0.17 ng/mL [29].  
Ochratoxin A gained notice for human health due to the suspicion that it may be involved in the 
pathogenesis of Balkan endemic nephropathy (BEN) and of certain other forms of interstitial   
nephritis [30]. BEN is a chronic tubulointerstitial kidney disease that occurs in some areas of Bosnia 
and Herzegovina, Bulgaria, Croatia, Romania, Serbia, and Monte Negro [31]. To clarify the role of 
OTA in BEN initiation, studies in these countries focused on endemic BEN regions. Results 
demonstrated that OTA was more frequently found in food from endemic areas as compared to   
non-endemic areas [18–21,32,33]. An investigation of OTA in blood from people living in endemic 
and non-endemic areas in Bulgaria in 1984, 1986, 1989, and 1990, showed that OTA was present in all 
groups. However, it was more frequently found and at higher levels in blood samples from BEN 
patients compared to blood samples from non-affected people in endemic and control areas [34]. The 
detected OTA blood levels of healthy humans, included in this study, were in the range of   
1.0–10.0 ng/mL and were supported by a later investigation of Petkova-Bocharova et al. [35]. Sixteen 
healthy volunteers who lived in two villages located in Vratza District (a high risk area for BEN in 
Bulgaria) had average serum concentration of 1.59 ng/mL (standard deviation: sd = 0.44). The 
medians were 0.4 ± 0.22 (sd = 0.22) and 0.7 (sd = 0.15) in the two villages [35]. In Croatia, the 
presence of OTA in the blood of inhabitants from the endemic and non-endemic regions had been 
monitored for 10 years. In the hyperendemic village Kaniza, the incidence of OTA in human blood 
was up to 4.5% (range of OTA concentrations: 2–50 ng/mL). In non-endemic villages OTA in human 
blood was identified in 2.4% (range: 2–10 ng/mL) [36]. In Sahel, an agricultural region of Tunisia, 
characterized by high incidences of chronic interstitial nephropathies of unknown etiology, highest 
OTA levels were found among people not affected by the nephropathy [37]. Comparing the OTA 
blood levels in individuals residing in BEN endemic areas with those found from areas without 
endemic nephropathy, there is no convincing evidence that OTA blood level may play a role in 
endemic nephropathy. A limitation of these studies is, however, that the role of OTA often was Toxins 2010, 2                                       
 
 
782
assessed indirectly by comparing villages and not affected patients with controls. This motivated us to 
test the OTA-BEN association by measuring serum OTA in BEN-patients, offspring of BEN patients 
and controls. In addition, we determined whether β2-microglobulin excretion, a clinical marker for 
nephropathy, is related to OTA serum levels. 
When assessing whether a factor “A” is a risk for disease “B”, “A” is considered a risk for “B” if 
there is a positive association between “A” and “B”. A concern in these studies is reverse causation: 
“B” may be a risk for “A” and not “A” for “B”. Reverse causation results from changes due to disease 
characteristics or disease behavior. For instance, higher serum OTA levels may result from reduced 
glomerular filtration [38]. The time-structure can help to decipher what comes first. However, when 
linking concurrently measured biomarkers such as OTA and β2-microglobulin, a time-order cannot be 
established since both characteristics are measured at the same time. To avoid false interpretation, it 
was decided not to focus on BEN patients, but to use another approach: Adult offspring of BEN 
patients and control patients, the latter being admitted to the Vratza hospital, were identified. The 
offspring did not have yet developed the BEN, thus excluding reverse causation. To consider the time 
order, OTA was measured once in 2005/2006, but β2-microglobulin was determined in the same 
individual twice, in 2005/2006 and in 2006/2007. Linking OTA levels in 2005/2006 with   
β2-microglobulin in 2006/2007 addresses the time order required in the assessment of health risks.  
In addition, the two offspring groups were followed until 2009. Of the 38 offspring of BEN patients, 
13 developed BEN themselves. This facilitated to assess the impact of OTA levels in 2005/2006 on the 
inception of the disease in 2009. 
2. Materials and Methods 
2.1. Material  
Ochratoxin A analyses  
Samples  
Samples of human blood were collected in clinical laboratory in Vratza. The samples were taken in 
2005 and 2006 at two time periods: 24 samples in April–July and 54 samples in October-March. All 
blood samples were centrifuged to separate serum and serum was stored at −20 °C. All samples were 
shipped frozen and stored at ≤−20 °C in the laboratory of the National Center of Public Health 
Protection, Sofia, until the analyses of ochratoxin A were conducted. A total of 78 serum samples were 
analyzed: 18 from BEN patients, 38 from BEN offspring, and 22 controls. We did not attempt to 
associate β2-microglobulin excretion in urine of BEN patients, since we were concerned that serum 
OTA level and β2-microglobulin excretion may be affected by the disease status. 
Reagents and consumables  
Crystalline ochratoxin A (CAS number 303-47-9) (Sigma-Aldrich Co.), OchraTest® (Vicam, USA) 
immunoaffinity columns; and chemical solvents (Merck, Germany) were of analytical or HPLC-grade 
quality. The following solutions were prepared: Phosphate buffered saline (PBS) (pH 7.4)—prepared 
by dissolving 7.0117 g NaCl, 0.2013 g KCl, 1.42 g Na2HPO4 in 1 L with purified water (adjusted pH Toxins 2010, 2                                       
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with HCl); Ochratoxin A stock solution was prepared by dissolving 1 mg of the ochratoxin A 
(crystals) in 50 mL toluene and glacial acetic acid (99 + 1, V + V). The exact concentration of the 
stock solution was determined specrophotometrically, recording maximum absorption between a 
wavelength of 300 nm and 370 nm, with solvent mixture as a reference in 1 cm quartz cell   
(MOTA = 403 g/mol,  = 544 m
2/mL). The solution was stored at 4 °C and its stability was monitored. 
A series of ochratoxin A working standard solutions in mobile phase, in the range of 20, 10, 8, 6, 4 and 
2 ng/mL were prepared on the day of analysis. 
Equipment 
Ochratoxin A analysis were carried out by a chromatographic system consisting of Perkin Elmer 
series 200 pump, Rheodine model 7125 injector valve (50 L), and fluorescence detector Perkin Elmer 
3000 (Ex = 333 nm, Em = 477 nm), analytical column—Lichrosphere 100RP18 (250 × 4.6, 5 m, 
Merck, Germany). 
2.2. Methods 
2.2.1. Ochratoxin A analysis in serum 
The samples were analyzed for the presence of OTA by immunoaffinity column clean-up and 
subsequent HPLC separation with fluorescence detection based on the method of Zimmerli and   
Dick [39], with some modifications: we worked with OchraTest® (Vicam, USA) immunoaffinity 
column, instead of those used in the study of Zimmerli and Dick [39]. Briefly: 2 mL serum was 
extracted by 10 mL chloroform after adding 10 mL of solution containing o-phosphoric acid and NaCl 
[39] on Vortex. The mixture was centrifuged at 1540 g for 20 m. The clear organic phase was 
evaporated to dryness at 60 °C (Rotavapor). The dry residue was redissolved in 20 mL solution of  
PBS + methanol (75 + 15, V + V) and was loaded on the IAC. The sample extract was passed trough 
the IAC (ca.1–2 drops/s) using a pump stand (Vicam, USA). After washing of the IAC with 10 mL of 
water, the OTA was eluted with 2 mL
 methanol. The eluate was evaporated to dryness under a stream 
of nitrogen and was stored at 4 °C until HPLC determination. 
Chromatographic conditions 
For the analytical column, available in our lab, we used a more appropriate mobile phase for HPLC: 
acetonitrile + distilled water + glacial acetic acid (100 + 98 + 2, V + V + V). Flow rate was 1 mL/min, 
isocratic elution. Temperature: ambient; injection volume: 50 L. The dry residue was carefully 
dissolved in 200 L of mobile phase.  
Method parameters: During implementation of the HPLC method were elaborated blank and spiked 
samples at three different concentration levels—0.2, 0.4, 0.6 ng OTA/mL serums.  The achieved 
recovery was 93.0%  10%.  
Linearity: Linearity was determined by a series of standards injection at six different concentrations 
in the range 2 ng/mL–20 ng/mL. The calibration curve showed a good linear relationship between 
peak height and OTA concentration with coefficient of correlation R
2 > 0.999. Toxins 2010, 2                                       
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Limit of detection (LOD): with the described procedure the detection limit was 0.1 ng/mL, based on 
3:1 signal to noise ratio. 
Calculated RSD, on the base of spiked samples was 5%. 
2.2.2. β2-microglobulin in urine 
β2-microglobulin in urine is a marker of impaired inability of the kidneys to re-absorb. Briefly, 
urine collected during the first hour of the 4-hour period [40], was analyzed for β2-microglobulin using a 
chemiluminescent immunoassay (Cat. No.LKBM1, DPC, USA) with the Immulite analyzer   
(DPC, USA).  
Statistical Methods 
Because the distributions of serum-OTA and β2-microglobulin in urine were not normal, we present 
their medians, conducted log-transformations, and used geometric means and their confidence limits. 
To answer the first question, whether BEN patients and offspring of BEN parents had higher serum 
OTA levels, we compared three groups (BEN patients, offspring of BEN patients, and offspring of 
control patients) using linear regression analyses (PROC GLM) [41]. Controlling for age, sex of the 
participant, and season of sample collection, we estimated the adjusted geometric means of the three 
groups. To answer the second question, whether β2-microglobulin in urine, a marker for kidney 
function [40] that was measured in offspring only, is related to OTA in serum, we also applied linear 
regression. After testing linearity, age was treated a continuous predictor of β2-microglobulin. Month 
of sample collection was grouped into “October to March” and “April to July”. Statistically controlling 
for age, sex of the participant, and season of sample collection, linear regression analyses provided the 
slope (parameter estimate) between OTA exposure and β2-microglobulin. In addition, to compare the 
extent to which β2-microglobulin measured in 2005/2006 and 2006/2007 were correlated we estimated 
Spearman rank correlations. Finally, we compared OTA serum levels measured in 2005/2006 in 
disease-free adult offspring; some of them later, after 2008, definitely or possibly developed BEN. All 
statistical analyses were performed using SAS 9.2 [41].  
3. Results and Discussion  
3.1. Results 
3.1.1. Population 
OTA serum levels were measured in 78 participants in 2005/2006; 18 were BEN patients,   
38 offspring of BEN patients and 22 were offspring of hospital controls who had other diseases (Table 1). 
BEN patients were approximately 20 years older (72.5 years) than the adult offspring of BEN and  
non-BEN patients (controls). In addition, in the offspring group with OTA serum determinations (n = 60: 
38 + 22), β2-microglobulin levels were measured in 59 subjects in 2005/2006 (37 BEN and 22 control 
offspring) and again in 58 subjects in 2006/2007 (36 BEN and 22 control offspring). 
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3.1.2. Ochratoxin A and β2-microglobulin analysis  
Table 1. Population characteristics. 
 BEN 
patients 
n = 18 
Offspring of 
BEN patients 
n = 38 
Offspring of 
controls patients 
n = 22 
Age in years, median 
(5%–95% values) 
Gender, % (male) 
Months of collection 
April–July, % 
October–March, % 
72.5 
(61.0–79.0) 
55.6 (10/18) 
 
22.2 
78.8 
49.0 
(38.0–63.0) 
57.9 (22/38) 
 
50 
50 
51.0 
(35.0–61.0) 
63.6 (14/22) 
 
4.5 
95.5 
Ochratoxin A in serum (ng/mL) 
median (5–95% values) 
β2-microglobulin in urine 2005/2006 
(ng/mL), median (5%–95% values) 
β2-microglobulin in urine 2006/2007 
(ng/mL), median (5%–95% values) 
1.15 
(0.40–3.90) 
- 
 
- 
0.70 
(0.30–1.80) 
51.00 
(12.30–500.00) 
56.55 
(14.60–500.00) 
0.56 
(0.39–0.93) 
50.25 
(22.40–152.00) 
34.75 
(14.90–156.00) 
 
By chance, only few samples from the offspring of the control patients were collected between 
April and July. In two families, both BEN patients and offspring participated. However, they were not 
living together in the same household and their values did not show a substantial agreement   
(family 1: BEN patient: 3.9 ng OTA/mL serum; offspring: 0.7 ng OTA/mL serum; family 2: BEN 
patient: 3.1 ng OTA/mL serum; offspring: 1.4 ng OTA/mL serum). For this reason, we did not adjust 
for coming from the same family. 
All of the tested BEN patients had detectible OTA serum levels, and the values are in the range of 
0.4 ng/mL to 3.9 ng/mL, with median of 1.15 ng/mL (adjusted geometric mean: 1.19 ng/mL, Table 2). 
Serum OTA was also significantly higher in BEN patients compared to adult offspring of BEN and 
non-BEN patients. The highest OTA level found was 3.9 ng/mL in the serum of a BEN patient. In the 
group of BEN offspring, the median was 0.70 ng/mL (adjusted geometric mean: 0.76 ng/mL), and only 
one sample is <LOD (0.1 ng/mL). In controls the median was 0.56 ng/mL (adjusted geometric mean:  
0.72 ng/mL), and two participants had OTA level <LOD. The season of serum collection affected the 
serum OTA concentration (Table 2). It was higher in samples collected in March to July.  
Table 2. Adjusted geometric means for ochratoxin A derived from linear regression analyses 
#. 
 Geometric  mean 
ng/mL 
5%–95% value 
ng/mL 
P-value 
(t-test) 
Season  
(March–July) 
(October–February) 
BEN patients (n = 18) 
Offspring of BEN patients (n = 38) 
Offspring of controls (n = 22) 
 
1.09 
0.69 
1.19 
0.76 
0.72 
 
0.86–1.37 
0.61–0.79 
0.86–1.66 
0.64–0.89 
0.56–0.92 
 
0.001 
 
0.02 
0.73 
reference 
# Adjusted for all variables above and age and sex of the participant. Toxins 2010, 2                                       
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The analysis of whether β2-microglobulin excretion is related to OTA focused on the group of adult 
offspring of BEN and non-BEN patients (Table 3). Complete data for all variables was available for  
56 of 59 participants in 2005/2006 and 55 of 58 in 2006/2007. The results show that serum OTA 
collected in 2005/2006 was significantly positively associated with β2-microglobulin in the same year 
and one year later. β2-microglobulin excretion was increased when participants were older. Sex of the 
participant and month of collection did not affect this association. The two measurements of   
β2-microglobulin in 2005/2006 and 55 of 58 in 2006/2007 were correlated (Spearman rank correlation 
coefficient: 0.55, p = 0.0001, n = 58), which indicate some stability over time. 
Table 3. Results of linear regression analyses. 
Parameter estimates explaining log10 of β2–microglobulin in urine (ng/mL) 
#  
  2005–2006 (n = 56)  2006–2007 (n = 55) 
Predictor  Parameter 
estimated 
P-value Parameter 
estimated 
P-value 
Serum OTA, (ng/mL) 
Age (per year) 
Sex (female) 
0.49 
0.016 
−0.014 
0.002 
0.01 
0.18 
0.36 
0.019  
−0.017 
0.0496 
0.01 
0.89 
April–July  −0.17 0.14  0.08 0.56 
# Mutually adjusted for all variables above. 
 
Since the risk of developing BEN is considered to be much higher in offspring of BEN patents, we 
followed offspring of BEN patients and offspring of control patients with yearly examination after 
2008. Of the 60 offspring (Table 1), we have information on 57 participants (38 offspring of BEN 
patients and 22 offspring of control patients). Of the initially BEN-free offspring, 13 developed BEN 
(six definite and seven suspected cases). OTA serum concentration showed a dose-response relation 
with the likelihood of BEN (no, suspected, definite; Table 4). Higher levels of OTA in 2005/2006 
were related to an increased certainty of BEN incidence (p = 0.0012).  
Table 4. Ochratoxin A in serum of participants in 2005/2006 and incidence of Balkan 
Endemic Nephropathy in 2009. 
Serum Ochratoxin A (OTA) levels in disease-free and incident cases 
 
Non BEN 
n = 44 
Suspected BEN 
n = 7 
Definite BEN 
n = 6 
Exposure  median 
5%–95% 
values 
median 
5%–95% 
values 
median 
5%–95% 
values 
Serum OTA in 
2005/2006 
(ng/mL) 
0.60 0.33–1.0 0.94 0.46–1.7  1.15 0.67–2.0 
Kruskal-Wallis test: P-value = 0.0012. 
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3.2. Discussion 
Our findings show that ochratoxin A serum levels were significantly higher in BEN patients 
compared to offspring of BEN patients and offspring of control patients. Within a population of adult 
offspring of BEN and non-BEN patients, OTA was statistically significantly related to higher   
β2-microglobulin excretion in urine. The association was not restricted to a concurrent effect (both 
markers measured at the same time) but also showed delayed affect. Hence, it is possible that OTA 
exposure may have a long-term toxic effect on the kidneys [2]. Although in 2005/2006, the serum 
concentration of OTA did not differ between offspring of BEN patients and offspring of control 
patients, OTA levels in 2005/2006 were associated with the incidence of BEN after 2008.  
Limitations are that the age of BEN patients, given the occurrence of BEN later in life, is higher 
(72.5 years) than the age of offspring of BEN patients and offspring of control patients (approximately 
50 years). However, also controlling for age, OTA levels were significantly higher in BEN patients. 
Another limitation is uneven distribution of OTA samples during the year. We were surprised to find 
serum OTA levels in participants were higher during March to July compared to October to February. 
Seasonal variability with higher OTA levels in blood serum/plasma in summer has been demonstrated 
by studies conducted in Italy, Croatia, and Spain [25,42–44]. In Tuscany, Italy, the OTA serum levels 
found in October were 34% lower than those found in July. In Croatia the levels found in December 
were 51% lower than those found in June. The finding that OTA levels were higher in summer and 
lower in winter may reflect changes in conditions favoring mould growth and toxin production [45]. 
Additionally, the period of time between harvesting and consumption of cereals may contribute to 
seasonal variation in OTA exposure. Cereals consumed during June will probably have been stored 
since the previous year, during which time the growth of OTA producing mould species can occur. In 
contrast, cereals consumed between September and December is likely to have been harvested more 
recently and is therefore a lower risk for OTA contamination [45]. Nevertheless, we adjusted the OTA 
levels for the effect of season and thus minimized this bias. 
The analytical parameters of the method for OTA determination, implemented in our laboratory 
(LOD 0.1 ng/mL, recovery 93%) are comparable with recent methods used in this field. The 
immunoaffinity clean-up and the HPLC separation and fluorescence detection give the advantage of 
sensitivity and specificity.  
Regarding serum OTA, our findings support the results of an earlier study performed in Bulgaria [34]. 
However, the highest value found in our study (3.9 ng/mL in one BEN patient) is only half of the 
highest value found in the study of Petkova-Bocharova et al. [35] in the healthy people residing in the 
same region in which our study was conducted. Comparing our results to a Croatian investigation that 
focused on the endemic village Kaniza and some non-endemic villages, our result are closer to the 
lowest value found in non-endemic villages (2 ng/mL) [36]. In addition, the levels we measured are 
comparable to levels reported in other European countries, excluding the higher values found in 
Poland (13.0 ng/mL) [22] and in Italy (57.2 ng/mL) [25].  
Within the adult offspring of BEN and non-BEN patients, OTA was statistically significantly 
related to higher β2-microglobulin excretion in urine. A higher β2-microglobulin is considered a 
marker of reduced kidney function [40]. Hassen et al. [46], conducted an investigation in Tunisia, a 
region considered to have higher OTA exposure, in patients with chronic interstitial nephropathy. The Toxins 2010, 2                                       
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investigators did not directly linked OTA and ß2-microglobulin, but showed that both are higher in 
spot urine samples of patients with chronic kidney diseases [46]. In two healthy control groups, the 
mean OTA levels were 2.6 ng/mL and 1.2 ng/mL; in disease patients the mean OTA levels were 44.4, 
8.11, 50.4, and 12.4 ng/mL. The median OTA levels in our study were 1.15 ng/mL for BEN patients, 
and 0.7 ng/mL for BEN offspring. In two healthy control groups in the Tunisian study, the mean  
ß2-microglobulin levels were 90 ng/mL and 120 ng/mL; in diseased patients the mean ß2-microglobulin 
levels were 2350, 710, 1960, and 1440 ng/mL. The median ß2-microglobulin level in our study were 
about 51–56 ng/mL for BEN offspring. We cannot explain why OTA, ß2-microglobulin and levels 
found by Hassen et al. [46] in an agricultural region of Tunisia were much higher than the levels in our 
study. It is possible, that to some extent the higher levels in the Tunisian study are due to use of means 
instead of medians in the case of skewed OTA distributions. 
In addition, an Egyptian study on OTA in both human milk and infant serum showed a statistical 
significant association between OTA levels in maternal milk and β2-microglobulin in serum of their 
infants [47]. ß2-microglobulin levels in infants of OTA positive mothers (n = 36) were 260 µg/mL and 
30 µg/mL in infants of mothers without detectable OTA concentration (n = 14). The difference was 
not statistically significant different when the investigators applied logistic regression analyses and 
controlled for other factors. 
Comparing a high risk group of adult offspring from parents who had BEN and a group of offspring 
of control patients without history of BEN, our follow-up study demonstrated for the first time, that 
serum concentration of OTA may contribute to the development of BEN. In adult offspring, who did 
develop BEN in 2009, OTA levels in 2005/2006 were twice the level of those who did not develop the 
disease. Since there were no differences in the two offspring groups in 2005/2006 and since all new 
BEN cases occurred in offspring with a family history, it is likely the OTA does not act alone but in 
combination with family predisposition.  
Although attention has focused on the OTA-BEN association, other nephrotoxic mycotoxins should 
not be ignored. For instance citrinin, a nephrotoxic mycotoxin produced by Aspergillus, Penicillum 
and Monascus spp., has been given comparatively less consideration. However, it is similar to OTA in 
its toxicology and both toxins may have additive or synergistic effects [48–51]. Citrinin was found in 
food sampled in the BEN area in Bulgaria [18]. Later, in this area, contamination of food by high 
levels of citrinin was confirmed in a study by Vrabcheva et al. [19]. Summarizing these data,   
Pfohl-Leszkowicz et al. [52] noted that areas in Bulgaria affected by BEN are characterized by a more 
frequent exposure to both OTA and citrinin.  
4. Conclusions  
Our study provides evidence that OTA levels pose a risk for developing the disease and are higher 
in BEN patients. The observation that the season of sample collection may affect the serum OTA 
concentration needs to be taken into account in the future studies. In particular, results form regional 
comparisons may be compromised by seasonal effects. The reported association between OTA and  
β2-microglobulin was not restricted to a concurrent but also showed a delayed effect and additionally 
was observed in one other study. However, to better understand the role of mycotoxins in the 
pathogenesis of BEN, future studies should not only investigate ochratoxin A, but also citrinin. Toxins 2010, 2                                       
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